US drug company Mylan N.V. announced Tuesday it would acquire the international marketing rights to a once-monthly treatment for Multiple Sclerosis developed by an Israel’s Mapi Pharma.
Glatiramer Acetate Depot is a long-acting drug designed to replace daily injections with a once-a-month alternative for people suffering from relapsing-remitting MS.
Relapsing-remitting MS, or RRMS, accounts for 85 percent of all initial diagnoses of the disease, the companies said.
Mylan already sells a generic version of Teva Pharmaceuticals’ widely-used MS treatment, Copaxone. But, if GA Depot successfully completes its Phase III clinical trials, it will be formidable competition to both Copaxone and Mylan’s generic version.
Copaxone, the only non-interferon multiple sclerosis treatment, was developed by Teva Pharmaceuticals in the mid-1990s. (Weizmann Institute of Science/JTA)
Mapi chairman and CEO Ehud Marom said his company’s drug would ease treatment for MS patients by reducing the number of injections they have to take.
Sign up for the Tech Israel Daily
and never miss Israel's top tech stories
By signing up, you agree to the
terms
“GA Depot is expected to significantly improve the mode of treatment for patients with MS by reducing the number of injections, easing the treatment burden and increasing patient compliance,” Marom said according to the business daily Globes. “We look forward to working with Mylan to bring this important drug to MS patients.”
In a statement, Mylan president Rajiv Malik hailed GA Depot as an “important and welcomed treatment option,” that the company would add to its “already-strong portfolio of central nervous system products.”
The companies did not disclose how much Mylan was investing in Mapi, but the Haaretz daily put the figure at $20 million.
The partnership is subject to approval by the Israel Innovation Authority.
Responsibly covering this tumultuous time
As The Times of Israel’s political correspondent, I spend my days in the Knesset trenches, speaking with politicians and advisers to understand their plans, goals and motivations.
I'm proud of our coverage of this government's plans to overhaul the judiciary, including the political and social discontent that underpins the proposed changes and the intense public backlash against the shakeup.
Your support through The Times of Israel Community helps us continue to keep readers across the world properly informed during this tumultuous time. Have you appreciated our coverage in past months? If so, please join the ToI Community today.
~ Carrie Keller-Lynn, Political Correspondent
Yes, I'll join
Yes, I'll join
Already a member? Sign in to stop seeing this
You're a dedicated reader
We’re really pleased that you’ve read X Times of Israel articles in the past month.
That’s why we started the Times of Israel eleven years ago - to provide discerning readers like you with must-read coverage of Israel and the Jewish world.
So now we have a request. Unlike other news outlets, we haven’t put up a paywall. But as the journalism we do is costly, we invite readers for whom The Times of Israel has become important to help support our work by joining The Times of Israel Community.
For as little as $6 a month you can help support our quality journalism while enjoying The Times of Israel AD-FREE, as well as accessing exclusive content available only to Times of Israel Community members.
Thank you,
David Horovitz, Founding Editor of The Times of Israel
Join Our Community
Join Our Community
Already a member? Sign in to stop seeing this